Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

作     者：Freeman, C. L. Dixon, M. Houghton, R. Kreuzer, K-A Fingerle-Rowson, G. Herling, M. Humphrey, K. Boettcher, S. de Costa, C. S. Iglesias, V. Stilgenbauer, S. Gribben, J. Hallek, M. Goede, V. 

作者机构：Queen Mary Univ London John Vane Canc Ctr Barts Canc Inst Dept Haematooncol Charterhouse Sq London England Roche Prod Ltd Dept Biostat Welwyn Garden City Herts England Roche Prod Ltd Dept Stat Programming & Anal Welwyn Garden City Herts England German CLL Study Grp Ctr Integrated Oncol Cologne Bonn Germany Univ Hosp Cologne Dept Internal Med Cologne Germany F Hoffmann Roche Ltd Pharma Dev Oncol Basel Switzerland Roche Prod Ltd Pharma Dev Clin Sci Welwyn Garden City Herts England Univ Hosp Schleswig Holstein Campus Kiel Kiel Germany Roche Innovat Ctr Basel PS Roche Pharmaceut Res & Early Dev pRED Basel Switzerland Univ Ulm Dept Internal Med 3 Ulm Germany Ctr Integrated Oncol Koln Dept Internal Med 1 Bonn Germany Univ Cologne Cluster Excellence Cellular Stress Responses Agin Cologne Germany 

出 版 物：《LEUKEMIA》 (白血病)

年 卷 期：2016年第30卷第8期

页      面：1763-1766页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 10[医学] 

基　　金：NCI NIH HHS [P01 CA081534] Funding Source: Medline